These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29527530)

  • 61. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
    Hobson CA; Pierrat G; Tenaillon O; Bonacorsi S; Bercot B; Jaouen E; Jacquier H; Birgy A
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0044722. PubMed ID: 35980232
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Frequency of enzymes associated with reduced sensitivity to beta-lactam antibiotics in enterobacteria isolates, Caracas, Venezuela].
    Marcano D; De Jesús A; Hernández L; Torres L
    Rev Panam Salud Publica; 2011 Dec; 30(6):529-34. PubMed ID: 22358397
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evolution of β-lactamase-mediated cefiderocol resistance.
    Fröhlich C; Sørum V; Tokuriki N; Johnsen PJ; Samuelsen Ø
    J Antimicrob Chemother; 2022 Aug; 77(9):2429-2436. PubMed ID: 35815680
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular epidemiology of cefotaxime-resistant but ceftazidime-susceptible Enterobacterales and evaluation of the in vitro bactericidal activity of ceftazidime and cefepime.
    Marchisio ML; Liebrenz KI; Méndez ELA; Di Conza JA
    Braz J Microbiol; 2021 Dec; 52(4):1853-1863. PubMed ID: 34269999
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characterization of the plasmid genes blaT-4 and blaT-5 which encode the broad-spectrum beta-lactamases TEM-4 and TEM-5 in enterobacteriaceae.
    Sougakoff W; Petit A; Goussard S; Sirot D; Bure A; Courvalin P
    Gene; 1989 May; 78(2):339-48. PubMed ID: 2550326
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses.
    Alsenani TA; Rodríguez MM; Ghiglione B; Taracila MA; Mojica MF; Rojas LJ; Hujer AM; Gutkind G; Bethel CR; Rather PN; Introvigne ML; Prati F; Caselli E; Power P; van den Akker F; Bonomo RA
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0093022. PubMed ID: 36602311
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An analysis of why highly similar enzymes evolve differently.
    Majiduddin FK; Palzkill T
    Genetics; 2003 Feb; 163(2):457-66. PubMed ID: 12618385
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop.
    Poirel L; Naas T; Le Thomas I; Karim A; Bingen E; Nordmann P
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3355-61. PubMed ID: 11709308
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Multiple global suppressors of protein stability defects facilitate the evolution of extended-spectrum TEM β-lactamases.
    Brown NG; Pennington JM; Huang W; Ayvaz T; Palzkill T
    J Mol Biol; 2010 Dec; 404(5):832-46. PubMed ID: 20955714
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections.
    Bush K
    Crit Care; 2010; 14(3):224. PubMed ID: 20594363
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Structure, function, and inhibition along the reaction coordinate of CTX-M beta-lactamases.
    Chen Y; Shoichet B; Bonnet R
    J Am Chem Soc; 2005 Apr; 127(15):5423-34. PubMed ID: 15826180
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Elucidating the role of Trp105 in the KPC-2 β-lactamase.
    Papp-Wallace KM; Taracila M; Wallace CJ; Hujer KM; Bethel CR; Hornick JM; Bonomo RA
    Protein Sci; 2010 Sep; 19(9):1714-27. PubMed ID: 20662006
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Structural Basis for Different Substrate Profiles of Two Closely Related Class D β-Lactamases and Their Inhibition by Halogens.
    Stojanoski V; Chow DC; Fryszczyn B; Hu L; Nordmann P; Poirel L; Sankaran B; Prasad BV; Palzkill T
    Biochemistry; 2015 Jun; 54(21):3370-80. PubMed ID: 25938261
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A secondary drug resistance mutation of TEM-1 beta-lactamase that suppresses misfolding and aggregation.
    Sideraki V; Huang W; Palzkill T; Gilbert HF
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):283-8. PubMed ID: 11114163
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interaction of cefdinir with beta-lactamases.
    Labia R; Morand A
    Drugs Exp Clin Res; 1994; 20(2):43-8. PubMed ID: 7924895
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Extended-spectrum beta-lactamases: an actual problem of hospital microbiology (a review).
    Szabó D; Barcs I; Rozgonyi F
    Acta Microbiol Immunol Hung; 1997; 44(4):309-25. PubMed ID: 9554165
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predictive analysis of ceftazidime hydrolysis in CTX-M-type beta-lactamase family members with a mutational substitution at position 167.
    Kimura S; Ishii Y; Tateda K; Yamaguchi K
    Int J Antimicrob Agents; 2007 Mar; 29(3):326-31. PubMed ID: 17258896
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.
    Tooke CL; Hinchliffe P; Lang PA; Mulholland AJ; Brem J; Schofield CJ; Spencer J
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383664
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
    Kang CI; Cha MK; Kim SH; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2014 May; 43(5):456-9. PubMed ID: 24690213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.